



Pharmaron Beijing Co., Ltd.

Pharmaron Beijing Co., Ltd. (the “Issuer”)

USD 300 Million Zero Coupon Convertible Bonds due 2026

(ISIN: XS2352395748) (the “USD Bonds”) and

RMB 1,916 Million USD Settled Zero Coupon Convertible Bonds due 2026

(ISIN: XS2353011724) (the “RMB Bonds”)

(together, the “Bonds”)

Notice to the Trustee and the Principal Agent

Capitalised terms not otherwise defined in this notice shall have the meaning given to them in the terms and conditions of the Bonds (the “Conditions”).

In accordance with the Trust Deeds of the Bonds, each executed on 18 June 2021 and pursuant to the Conditions, the Issuer hereby gives notice pursuant to Clause 6.1 of the Trust Deeds that, as a result of the Board resolution, on 30 March 2023, to declare a final dividend (the “**Final Dividend**”) comprising of (i) a cash dividend of RMB 3.0 (inclusive of tax) per 10 Ordinary Shares and (ii) 5 new Ordinary Shares for every 10 existing Ordinary Shares to be issued out of reserve to all Shareholders, pursuant to Condition 5.3.2(i) and Condition 5.3.3 an adjustment will be triggered to the Conversion Prices of each of the Bonds, subject to approval of the Final Dividend at the general meeting of Shareholders.

The date of submission of the Final Dividend for approval at the general meeting of Shareholders is expected to be 2 June 2023.

The Conversion Prices in effect for each of the Bonds at the time of this notice are:

- HKD 166.42 per Share for the USD Bonds
- HKD 152.32 per Share for the RMB Bonds

A further notice will be issued once the exact date of submission for approval is announced.

30 March 2023

For and on behalf of

Pharmaron Beijing Co., Ltd.

(康龙化成(北京)新药技术股份有限公司)

Authorised Signatory

Name: LI Shing Chung Gilbert

Title: Chief Financial Officer

8th Floor, Block 1

6 Tai-He Road

Beijing Economic Technological Development Zone

Beijing, China